Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription


1 Am J Respir Crit Care Med
2 Cancer Cell
1 Cancer Sci
2 Chest
1 Clin Cancer Res
21 Clin Lung Cancer
1 Eur J Cancer
1 Hum Pathol
1 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
1 J Thorac Cardiovasc Surg
1 J Thorac Oncol
2 Lancet Oncol
1 Lung Cancer
1 Nat Med
5 Oncogene
1 Oncol Rep

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Respir Crit Care Med

  1. KAMMER MN, Lakhani DA, Balar AB, Antic SL, et al
    Integrated Biomarkers for the Management of Indeterminate Pulmonary Nodules.
    Am J Respir Crit Care Med. 2021;204:1306-1316.
    PubMed         Abstract available

    Cancer Cell

  2. LE X, Nilsson MB, Robichaux JP, Heymach JV, et al
    ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC.
    Cancer Cell. 2021;39:1178-1180.
    PubMed         Abstract available

  3. MOORE AR, Malek S
    The promise and peril of KRAS G12C inhibitors.
    Cancer Cell. 2021;39:1059-1061.
    PubMed         Abstract available

    Cancer Sci

  4. KANAYAMA M, Kuwata T, Mori M, Nemoto Y, et al
    Prognostic impact of circulating tumor cells detected with the microfluidic "Universal CTC-chip" for primary lung cancer.
    Cancer Sci. 2021 Dec 29. doi: 10.1111/cas.15255.
    PubMed         Abstract available


  5. OMBALLI M, Ramaniuk A, Patel DC, Ataya A, et al
    A 29-Year-Old Woman With Cough, Dry Eyes, Pulmonary Cysts, and Nodules.
    Chest. 2021;160:e195-e198.
    PubMed         Abstract available

    Malignant Pleural Effusion in Malignant Pleural Mesothelioma: An Innocent Bystander?
    Chest. 2021;160:1602-1603.

    Clin Cancer Res

  7. DI NOIA V, Pimpinelli F, Renna D, Barberi V, et al
    Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
    Clin Cancer Res. 2021;27:6815-6823.
    PubMed         Abstract available

    Clin Lung Cancer

  8. SAMUEL E, Lie G, Balasubramanian A, Hiong A, et al
    Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
    Clin Lung Cancer. 2021;22:e425-e430.
    PubMed         Abstract available

  9. GADOTTI LL, Nogueira Amorim Canedo FS, Ribeiro MFSA, Sacardo KP, et al
    Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e481-e486.

  10. ZENG YW, Liu Y, Qi Y, Yin MP, et al
    Bronchial Arterial Infusion Chemotherapy Plus Drug-eluting Bead Chemoembolization for Recurrence of Carina Region-induced Severe Right Main Bronchial Stenosis After Pneumonectomy.
    Clin Lung Cancer. 2021;22:e293-e297.

  11. BEHRENS C, Rocha P, Parra ER, Feng L, et al
    Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e415-e424.
    PubMed         Abstract available

  12. PENG LP
    Regarding: MicroRNA-126 Targeting PIK3R2 Inhibits NSCLC A549 Cell Proliferation, Migration, and Invasion by Regulation of PTEN/PI3K/AKT Pathway.
    Clin Lung Cancer. 2021;22:e446-e450.

  13. CHAPMAN BV, Ning MS, Farnia B, Mesko S, et al
    Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields.
    Clin Lung Cancer. 2021;22:225-233.
    PubMed         Abstract available

  14. PATEL A, Roshkovan L, McNulty S, Alley E, et al
    Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study.
    Clin Lung Cancer. 2021;22:210-217.
    PubMed         Abstract available

  15. ZHOU M, Joshi N, Raj KP, Wakelee H, et al
    PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.
    Clin Lung Cancer. 2021;22:e329-e335.

  16. TAMIYA A, Isa SI, Taniguchi Y, Nakagawa H, et al
    Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
    Clin Lung Cancer. 2021;22:e336-e341.
    PubMed         Abstract available

  17. KUNTE S, Stevenson J
    A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib.
    Clin Lung Cancer. 2021;22:e298-e300.

  18. KANDER EM, Shah MH, Zhou Y, Goyal A, et al
    Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
    Clin Lung Cancer. 2021;22:e442-e445.

  19. TSUTANI Y, Nakayama H, Ito H, Handa Y, et al
    Long-Term Outcomes After Sublobar Resection Versus Lobectomy in Patients With Clinical Stage IA Lung Adenocarcinoma Meeting the Node-Negative Criteria Defined by High-Resolution Computed Tomography and [(18)F]-Fluoro-2-Deoxy-d-Glucose Positron Emissio
    Clin Lung Cancer. 2021;22:e431-e437.
    PubMed         Abstract available

  20. COUDERC AL, Tomasini P, Nouguerede E, Rey D, et al
    Older Patients Treated for Lung and Thoracic Cancers: Unplanned Hospitalizations and Overall Survival.
    Clin Lung Cancer. 2021;22:e405-e414.
    PubMed         Abstract available

  21. KOZLOV A, Pantel A, Iagaru A, Ikeda D, et al
    Pulmonary Adenocarcinoma Metastasis to the Breast Unexpectedly Discovered on Re-staging (18)F-FDG PET/CT in a Woman With a Normal Screening Mammogram.
    Clin Lung Cancer. 2021;22:e438-e441.

  22. XIE Z, Gu Y, Xie X, Lin X, et al
    Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.
    Clin Lung Cancer. 2021;22:e390-e394.

  23. WHITE MN, Piotrowska Z, Stirling K, Liu SV, et al
    Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
    Clin Lung Cancer. 2021;22:201-209.
    PubMed         Abstract available

  24. PRINZI N, Rossi RE, Proto C, Leuzzi G, et al
    Recent Advances in the Management of Typical and Atypical Lung Carcinoids.
    Clin Lung Cancer. 2021;22:161-169.
    PubMed         Abstract available

  25. RIESS JW, Rolfo C, Gandara DR
    Novel Clinical Trial Designs in Pursuit of Precision Oncology: Lung-MAP As a Model.
    Clin Lung Cancer. 2021;22:153-155.

  26. CATANIA C, Muthusamy B, Spitaleri G, Del Signore E, et al
    The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
    Clin Lung Cancer. 2021 Nov 11. pii: S1525-7304(21)00279.
    PubMed         Abstract available

  27. HEYNEMANN S, Yu H, Churilov L, Rivalland G, et al
    NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort.
    Clin Lung Cancer. 2021 Nov 16. pii: S1525-7304(21)00281.
    PubMed         Abstract available

  28. WANG S, Wu X, Zhao J, Chen H, et al
    Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.
    Clin Lung Cancer. 2021;22:e366-e370.

    Eur J Cancer

  29. IWAMA E, Zenke Y, Sugawara S, Daga H, et al
    Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Eur J Cancer. 2021;162:99-106.
    PubMed         Abstract available

    Hum Pathol

  30. WANG B, Chen R, Wang C, Guo J, et al
    Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients.
    Hum Pathol. 2021;114:90-98.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  31. WANG Y, Zhang T, Huang Y, Li W, et al
    Real-world Safety and Efficacy of Consolidation Durvalumab after Chemoradiotherapy for Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Int J Radiat Oncol Biol Phys. 2021 Dec 26. pii: S0360-3016(21)03422.
    PubMed         Abstract available

    J Clin Oncol

  32. DEVARAKONDA S, Li Y, Martins Rodrigues F, Sankararaman S, et al
    Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
    J Clin Oncol. 2021;39:3747-3758.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

  33. CHEN J, Soultanis KM, Sun F, Gonzalez-Rivas D, et al
    Outcomes of sleeve lobectomy versus pneumonectomy: A propensity score-matched study.
    J Thorac Cardiovasc Surg. 2021;162:1619-1628.
    PubMed         Abstract available

    J Thorac Oncol

  34. CHO BC, Han JY, Kim SW, Lee KH, et al
    A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2021 Dec 24. pii: S1556-0864(21)03403.
    PubMed         Abstract available

    Lancet Oncol

  35. PORTA C, Nardone V, Gray SG, Correale P, et al
    RAMES study: is there really a role for VEGF inhibition in mesothelioma?
    Lancet Oncol. 2021;22:e532.

  36. ZUCALI PA, Pinto C, Ceresoli GL
    RAMES study: is there really a role for VEGF inhibition in mesothelioma? - Authors' reply.
    Lancet Oncol. 2021;22:e533.

    Lung Cancer

  37. RIUDAVETS M, Naigeon M, Texier M, Dorta M, et al
    Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
    Lung Cancer. 2021 Dec 3. pii: S0169-5002(21)00624.
    PubMed         Abstract available

    Nat Med

  38. FORDE PM, Anagnostou V, Sun Z, Dahlberg SE, et al
    Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
    Nat Med. 2021;27:1910-1920.
    PubMed         Abstract available


  39. ROUKENS MG, Frederiks CL, Seinstra D, Braccioli L, et al
    Regulation of a progenitor gene program by SOX4 is essential for mammary tumor proliferation.
    Oncogene. 2021;40:6343-6353.
    PubMed         Abstract available

  40. LEONARD MK, Puts GS, Pamidimukkala N, Adhikary G, et al
    Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.
    Oncogene. 2021 Aug 25. pii: 10.1038/s41388-021-01998.
    PubMed         Abstract available

  41. TAKAGI S, Sasaki Y, Koike S, Takemoto A, et al
    Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis.
    Oncogene. 2021;40:5548-5558.
    PubMed         Abstract available

  42. XU G, Yang Z, Ding Y, Liu Y, et al
    The deubiquitinase USP16 functions as an oncogenic factor in K-RAS-driven lung tumorigenesis.
    Oncogene. 2021;40:5482-5494.
    PubMed         Abstract available

  43. LI M, Li X, Goldsmith JR, Shi S, et al
    Decoupling tumor cell metastasis from growth by cellular pilot protein TNFAIP8.
    Oncogene. 2021;40:6456-6468.
    PubMed         Abstract available

    Oncol Rep

  44. SONODA D, Kamizaki K, Matsuo Y, Aruga K, et al
    Characterization of morphological alterations in micropapillary adenocarcinoma of the lung using an established cell line.
    Oncol Rep. 2022;47.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.